5.58 +0.04 (0.72%)
After hours: 7:50PM EDT
|Bid||5.55 x 1800|
|Ask||5.75 x 800|
|Day's Range||4.75 - 5.59|
|52 Week Range||3.22 - 7.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.83|
Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, will host an invitation-only symposium on portal hypertension for institutional investors and research analysts on Thursday, September 27, 2018, from 4:30 p.m. to 6:00 p.m. ET in New York. Guadalupe Garcia-Tsao, M.D., Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, and Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System, will address the clinical importance of portal hypertension.
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...
Conatus Pharmaceuticals Inc. (CNAT) has accepted invitations to participate in two upcoming investor conferences. At the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease (September 26-27 in New York), senior management will conduct a series of scheduled meetings with investment professionals. At the Roth Capital Partners Battle of the NASH Thrones Investor Conference (October 17 in New York), senior management will conduct a series of scheduled meetings with investment professionals and participate in a panel discussion on fibrotic, inflammatory and metabolic agents.
Every investor in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to seeRead More...
Conatus Pharmaceuticals (CNAT) needs investors to pay close attention to the stock based on moves in the options market lately.
Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it has been invited to present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference on Friday, September 7, 2018, in New York. Steven Mento, Ph.D., President and Chief Executive Officer of Conatus, is scheduled to present a corporate overview and business update at 10:30 a.m. ET. Host BioCentury handpicks only 48 companies to present their stories to biotech sector institutional investors.
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / U.S. markets were mixed on Wednesday, with the Dow Jones and S&P 500 finishing in the red, as the Federal Reserve meeting indicated another interest rate hike ...
Conatus (CNAT) delivered earnings and revenue surprises of 25.00% and -3.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of 15 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss ...
SAN DIEGO, Aug. 01, 2018-- Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results ...
On Conatus' (CNAT) second-quarter 2018 conference call, investor focus will remain on the company's progress with respect to its lead candidate, emricasan.
Conatus Pharmaceuticals Inc. (CNAT) today announced that it will report financial results for the second quarter ended June 30, 2018, after the market close on Wednesday, August 1, 2018. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Wednesday, August 1, 2018, to discuss the financial results and provide a corporate update. A live and archived audio webcast of the call will also be available in the Investors section of the Conatus website at www.conatuspharma.com.
Conatus Pharmaceuticals Inc. (CNAT) today announced the publication1 of results from preclinical studies of its pan-caspase inhibitor emricasan, demonstrating improvements in portal hypertension (elevated blood pressure in the vein flowing into the liver) and survival in two bile duct ligation mouse models of induced secondary biliary cirrhosis. In the first of the two current mouse studies, designed to evaluate treatment effect, emricasan decreased fibrosis, reduced portal hypertension and improved survival in mice with cirrhosis induced by bile duct ligation. The reductions in portal hypertension exceeded amounts that could be explained by the decreased fibrosis alone, indicating potential treatment effects both inside and outside the liver.
Conatus Pharmaceuticals (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The San Diego-based company said it had a loss of 17 cents per share. The results matched Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also for ...
Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.
Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.